Bioelectronics Corp (BIEL)

[bankrupt_2009]

Marketing Summary: BioElectronics (OTC Pink: BIEL) Paul Knopick, E & E Communications

Release #:812-107460-em-799242:


Marketing Summary: BioElectronics (OTC Pink: BIEL) Paul Knopick, E & E Communications


For your due diligence.
OTC Pink: BIEL
Emerging as the way to heal pain without drugs

Marketing Summary


· Back Pain

· Neck Pain

· Knee Pain

· Wrist Pain

· Smart Insole™
· Menstrual Pain

· Surgery & Wound Care

· Contactless™ TENS




BioElectronics Corporation, 4539 Metropolitan Court, Frederick, Maryland 21704
301-874-4890 | www.bielcorp.com | [e-mail]

Introduction



BioElectronics Corporation, www.bielcorp.com develops manufactures, markets and sells highly efficacious, cost/beneficial, and safe medical devices for chronic pain. These competitively priced analgesics provide superior pain relief compared to hot or cold therapies, and common high-risk pain medications. Globally, we are developing strong OTC brands that reflect a new profound market segment of products for the back, knee, other musculosketal and menstrual pain.



Clinically established, the wafer-thin, easy-to-wear, patented, drug-free, devices reduce pain, inflammation and accelerate healing. The Company’s technology platform is a pipeline of new product opportunities. In 2009, BioElectronics received a “Wall Street Journal Technology Innovation Award.”

The devices use proven therapies of heat and electric restoration of the body’s injured cells. Physicians, sports trainers, and therapist around the world have used pulsed shortwave therapy successfully for more than eighty years to reduce pain and inflammation and accelerate healing. The Company has reduced the clinic apparatus to wafer thin disposable devices that are applied directly to the body. The extended duration dual therapy of heat and electric restoration is significantly safer and more effective than competitive heat or cold pads and pain medications. The devices consist of an inexpensive microchip, battery and antenna that deliver the therapy more effectively. The retail market potential exceeds $1 billion worldwide.

Our devices provide 7-days of continuous pain relief for the following applications

Back Pain Therapy
Neck Pain Therapy;
Knee Pain Therapy;
Wrist and Elbow Pain Therapy;
Smart-In Sole™ for Heel Pain; and,
Allay™ Menstrual Cycle Pain Therapy.

The musculoskeletal devices and affixing wrap retail for $14.95 to $19.95. The Allay, monthly menstrual cycle device including two protective sleeves retails for $9.95.

ActiPatch and Allay Retail Sales and Distribution through Professionals - BioElectronics has engaged the Greenwood Group, a leading brand management and sales organization, to manage all of its retail sales, marketing and distribution operations.



The Greenwood Group, http://www.greenwood.com/ located in Buffalo New York, manages in excess of $250 million in retail sales that include Bayer, Morton Salt, Advanced Visio, Nice Pak, Kobayashi, Kids+Med, Hothands Heat-Max, and Hygenic. The brands that are owned by Greenwood include Breathe Right, Plax, Joint-ritis, Zone, and others. Its management has decades of senior retail experience in such notable companies as Bayer, Johnson & Johnson, The Gillette company, Novartis, and other leading OTC sales and marketers.



Greenwood works internationally with Ceuta International Distributor Alliance, http://www.ceutaalliance.com/index.html the Leading Global Outsource Solution Provider to the Health & Beauty Industry, and its extensive international network of 55+ retail sales and distribution companies. Greenwood will launch our campaigns in North America, Eastern and Western Europe, Middle East, Africa, and Asia, covering more than 400,000 pharmacies. Ceuta annual sales exceed £240 million and their outsource clients include GlaxoSmithKline, P&G, Reckitt Benckiser, Pfizer, Unilever, Sanofi Aventis, etc. We were invited to present our products and initiate our sales and marketing to the International Distributors Alliance on October 21, 2011 in Barcelona. These accomplished partners will position our products onto the right shelves quickly and efficiently. We have received good interest from the 25+ of the distributors and we are negotiating the agreements.



To Date, they have recruited the following sales and distribution organizations:

Ceuta Healthcare, Ceuta International Group’s sister company will sell and distribute in the U.K.
McCaughey Consumers Products http://www.mcptri.com sales and distribution firm with annual sales of approximately $50 million Canadian to sell and distribute the products in Canada. The products have been tested in the Canadian retail market at twice the price with very positive results.


Ready to Accelerate

The Company is prepared to accelerate during the next few months having achieved the following milestones:

· Leading management partners and distributors organized to sell and distribute the product in the retail market both domestically and internationally.

· Product has received a Technology Innovation Award by the Wall Street Journal – 2009.

· United States Food and Drug Administration (US FDA) market clearance for the treatment of edema. Three additional US FDA OTC market clearances pending for relief of menstrual cycle pain relief, for the relief of musculoskeletal pain and for post-operative pain and edema.

· Canadian market approval for relief of pain in musculoskeletal complaints and menstrual cycle pain in both medical and over-the-counter markets in addition to a post-surgery indications.

· CE Mark (European Common Market) Certification for the medical and over-the-counter markets in the entire European Union market.

· ISO 13485 Certification, aggressive off-shore component manufacturing in place with very substantial production capacity.

· Television commercials completed for Canadian and United Kingdom (U.K.) markets.

· Internet monthly shipment program implemented with very good results for the Allay™ Menstrual Pain Therapy product at $12.99 with free shipping.

· A proven innovative product design competence.



Market
An increased consumer awareness of the dangers of overuse of oral analgesics such as acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) has significantly altered the competitive landscape for pain management therapeutics. Many common anti-inflammatory pain medications are required to carry warning labels due to potential dangerous side-effects (and some have been withdrawn altogether). There is significant market opportunity for a therapeutic agent with improved efficacy and no side-effects. The distinctive value proposition of the products is the delivery of drug-free therapy that reduces pain and inflammation and accelerates healing by 30% to 50% when compared with the present standard methods of patient care. The market potential exceeds $10 billion worldwide.



Products

The Company conducts its marketing strategy in five principal product segments. It markets and sells its current products under the brand names, ActiPatch®, Allay™ and RecoveryRx™. Products for veterinary use are manufactured by the Company and marketed under the brand name HealFast™ by the eMarkets Group. The products, due to their unique design, packaging, and therapeutic healing characteristics, have applications across multiple markets and market segments; however, the consumer product lines are the focus. Specialized packaging and wraps have been developed to meet the needs of the major brands as outlined below:





Brand Name




Segment


Target Market


ActiPatch®


OTC Pain Relief-Back, Knee, Heel & Wrist


Consumer


Allay™


OTC Women’s Health/Menstrual Pain


Consumer


RecoveryRx™


Wounds & Post-Surgical Recovery


Medical Professionals


HealFast™


Veterinary/Animal Use


Veterinarian/Consumer








ActiPatch®- The most significant opportunity is presented by one of the most common human ailments, namely, musculoskeletal complaints. A key benefit of each of the products is portability, namely the complete mobility of the user while wearing the device. This portability feature of the product and mobility of the user enables a quicker functional return to regular activities resulting in less lost time from work, sports and other activities.

Back Pain – ActiPatch therapy is a highly effective treatment for the 50 – 60 million persons in the U.S. suffering from acute and chronic back pain. Patients suffering from back pain spend more than $90 billion annually in health-care expenses, with approximately $26 billion of that amount directly attributable to treating back pain. Each year, two percent of the U.S. work force has compensable back injuries. In Europe, lower back pain is a major health and socio-economic problem and the second leading cause of sick leave. An EU Commission study recently suggested that as many as 67 million people suffered pain in their lower or upper back in the previous week. The lifetime prevalence has been estimated to be between 59% to 90% of adults, and in any one year, the incidence of back pain is reported to be about 5.0% of the population, making effective solutions to back pain a very important market. Our advantage is that the market is currently dominated by therapies that offer temporary relief. Thermacare® is currently leading in the disposable pain-relief wrap category with almost 40% market share. Neither ThermaCare nor its competitive products make a specific medical claim as to any therapeutic benefits. Nonetheless, U.S. sales of ThermaCare exceed six million units. ActiPatch Back Pain Therapy offers long-term relief from pain at a fraction of the cost. We strongly believe ActiPatch is positioned well to compete within this space.

Neck and Upper Body Pain - Several competing brands already offer a Neck & Shoulder patch in their portfolio of products – and this indication is commonly their 2nd most popular product – behind only their back relief product.



According to Focused Health Solutions, Analgesics, acupuncture, exercise interventions and manual therapy have been proven to be useful as neck pain relief in short-term only. Depending on the specific case, ActiPatch has the potential to be the ONLY solution that offers sustained long-term neck pain relief. Easy to apply, and comfortable to wear, the ActiPatch Neck & Shoulder Therapy will provide continuous relief using BioElectronics’ patented BioDynamic therapy.



Knee Pain - Knee pain is one of the most common musculoskeletal issues that causes people to see their doctor, and with today's increasingly active and aging society, the number of knee problems people are experiencing is increasing. Costs in 2003 for all knee and joint replacement procedures were estimated at $24.8 billion. Knee pain is generally treated with ice or heat, rest and drug therapy. ActiPatch is an inexpensive, effective therapy that provides convenient pain relief and accelerated recovery.



Heel Pain- Plantar Fasciitis (heel pain) occurs in about 30 million Americans. The rate of the condition is raising rapidly both in the U.S. and Western Europe, as the condition is often related to obesity. We have created a two-part delivery system to successfully treat plantar fasciitis 24 hours a day. We have integrated the healing therapy of ActiPatch with the comfort and support of a gel insole for daytime wear and redesigned our heel wrap for maximum coverage during the night. Conjointly, this innovative system creates the ultimate pain relief and healing product.



Wrist Pain - An estimated 5% of the U.S. population (15 million people) suffers from carpal tunnel syndrome. This is not only a painful condition but costly, with an average lifetime cost, including medical bills and lost time from work, estimated to be about $30,000 per injured individual. ActiPatch Wrist Pain Therapy wrap is a convenient method of treating pain and can be worn comfortably under a splint wrist brace.



ActiPatch Market - One of the most common human ailments, namely, musculoskeletal complaints, presents - The most significant OTC opportunity. While this is especially true regarding the substantial market for treating back pain, additional opportunities exist in other types of musculoskeletal complaints such as sore knees, tennis elbow, heal and foot pain, and plantar fasciitis.



According to the U.S. National Institute for Occupational Safety and Health (NIOSH), back pain is one of the most common and significant musculoskeletal medical problems in the world. In fact, some 80% of adults seek professional care at some point for low back pain, and one third of all disability costs in the U.S. are due to lower back disorders. A surprisingly high 16.2 million office visits each year result from back pain conditions.



Other notable statistics that make the back pain sector of particular importance to the injury and healing products’ market include the following facts:

Back injuries are the leading cause of disability in the U.S. for people younger than 45 years of age and represent the most expensive health care problem for people between 20 years and 50 years old;
Approximately 1% of the U.S. population is chronically disabled due to back pain, and an additional 1% is temporarily disabled and;
Each year, 2% of the U.S. workforce has compensable back injuries.

Patients suffering from back pain consume more than $90 billion annually in health-care expenses, with approximately $26 billion of that amount directly attributable to treating back pain. Furthermore, a study by Duke University found the annual per capita expenditures for patients with back pain were 1.6 times higher than those without back pain. These increased expenditures were found in all categories including inpatient charges, office visits, prescription drugs, outpatient care, home health care and emergency room care. Back pain is classified into three categories, based on the duration of symptoms, as acute (pain that has been present for six weeks or less), sub-acute (a six- to 12-week duration) and chronic (longer than 12 weeks).



In Europe, the situation is no different. Lower back pain is a major health and socio-economic problem throughout the region and the second leading cause of sick leave. An EU Commission study recently suggested that a very significant 67 million people suffered pain in their lower or upper back in the previous week. The lifetime prevalence has been estimated at 59% to 90%, and in any one year, the incidence of back pain is about 5.0% of the population. Furthermore, while most episodes of low back pain settle after a couple of weeks, many have a recurrent course with further acute episodes affecting 20% to 44% of patients within one year in the working population and lifetime recurrences of up to 85%, making effective solutions to back pain a very important market.



The U.S. and European back market exceeds 130 million sufferers combined with systems for treating the knee, wrist, elbow and heel pain, the market exceeds several billions dollars annually.





Allay Menstrual Pain Therapy is a new, drug-free treatment for pain and discomfort associated with menstruation. Various researchers estimate 50% of women suffer from pain during menstruation, with millions of women experiencing pain severe enough to restrict their daily activities. Most women typically use acetaminophen or ibuprofen to treat pain associated with dysmenorrhoea (period pain), with many women taking or exceeding maximum dosages of these dangerous medications.



The drug-free Allay product is worn tucked into a woman's undergarments with the product’s flexible loop covering the site of pain. In the U.S., 25 million women stand to benefit from this pain relief patch. This product provides longer lasting relief than the Thermacare heat patch.





Allay Menstrual Pain and Market - Various researchers estimate 50% of women suffer from pain during menstruation, with millions of women experiencing pain severe enough to restrict their daily activities.



There are currently approximately 300 million people in the U.S. with roughly half or about 150 million representing women. Assuming approximately one third are of childbearing age, the total potential addressable market for the Company's Allay product becomes around 50 million women in the U.S. Gaining only a 10.0% market share of this segment would represent a significant market opportunity for the Company of approximately 2.5 million women.



Considering each Allay product lasts for one menstrual cycle, many women would purchase up to twelve units per year. At $150.00 annually for 12 units and a 10% market share, Allay could easily experience sales of $375 million per year in the U.S., with the European and other international markets likely being double the US market.
Proven Therapy



The BioElectronics devices stimulate the tissue to rapidly pass through the tissue-damaging phase of inflammation, moving the body into the tissue repair phase of natural healing. Inflammation occurs following soft tissue injuries such as accidental cuts or scrapes, surgical incisions, sprains and strains (including those of the lower back), and repetitive stress injuries such as plantar fasciitis (heel pain), carpal tunnel syndrome, tennis elbow and the like. The net effect is an acceleration of healing.





Heat Therapy - The use of pulsed electromagnetic therapy to generate heat in the body is significantly safer and more effective than topical heat or cold applications. The device uses radio frequency to penetrate and bypass the skins temperature regulatory mechanism. The microchip controls the RF dose to preclude excessive heat accumulation. The use of heat as a therapeutic agent has precedence as far back as traditional Chinese, Hindu and ancient Greek medicine, but recent biological research has provided a strong scientific foundation for the efficacy of this therapeutic modality. Medical diathermy, the use of electrical devices to push heat deep into the body, is as old as radio.





Eighty years ago, clinicians started pulsing the heat into the body to preclude burning the patients.


Increasing the RF pulse rate and you achieve a safe, steady, and controlled deep heating affect and maintain the non-thermal electrical affect.





In traditional diathermy, the heating doses used are very high to minimize clinical and operator treatment time. Lowering the dose down to the level necessary to stimulate a biological responsse, sustains pain refief and enables home use. Now the device can be battery operated utilize inexpensive wafer thin microhip electronics, allowing the device to lay directly over the injured tissue for maximum effectivenes. Clinical studies demonstrate superior pain relief and healing with lower power and extended duaration therapy. The dual thermal and electrical therapy of diathermy provides a a unique, dynamic approach to the reducttion of pain, inflammation and the acceleration of healing.



Tissue temperature increases can have several distinct effects on tissue behavior, though to a large degree, all of the physiologic effects of increasing the temperature of a biological tissue relate to conformational changes in protein and/or lipid structures and organization. Metabolic activities of all cellular processes are directly affected by tissue temperature and the change in biochemical activity that is directly related to tissue temperature. In brief, recent molecular biological, electrophysiological, and clinical research has demonstrated that the peripheral neural system is highly temperature sensitive, and many other specific sites and mechanisms of thermal sensitivity have been identified. This recent research points to a consensus understanding that a useful working range for ensuring significant biological responses to tissue heating is that the usual tissue temperature of 37oC should be raised at least 0.1oC. At the same time, the tissue temperature must be kept below 42oC to prevent cell damage. Application of these observations to the clinical setting suggests that a margin of safety be incorporated to ensure both the safety and efficacy of thermal therapeutics. Therefore, when core tissue heating is the objective, safe and efficacious tissue temperature increases should be kept in the range of approximately 0.3-3oC.



Electrical Therapy - When soft tissue is damaged, the cells leak fluid and cellular components break down. The cell’s electrical charge is diminished, causing normal cell functions and operations to shut down. Chemical signals that cause inflammation are released resulting in swelling (edema) and pain. The devices induce an indiscernible electrical current into these damaged cells at a frequency that recharges them, thus stopping the release of inflammatory mediators and reestablishing normal cell interaction. An immediate reduction in the swelling and inflammation occurs - a true and beneficial acceleration in the body’s normal healing process.
Competitive Product Analysis



There are no other products available at the price points of the Company’s products that address soft tissue injuries using PEMF therapy. Moreover, the current drugs and therapies that are available for managing pain and edema are only marginally effective. These ineffective solutions include:

Ice This therapy is messy and inconvenient. ActiPatch is simple, convenient, and portable for 24 hour of constant therapy particularly important during the initial inflammatory phase.



Hot/Cold treatments This therapy provides tactile comfort but has little therapeutic or long-term benefits. There are also burn safety issues.



Elastic bandages and neoprene support braces These products restrict movement and provide support to allow the tissue to heal. Unlike ActiPatch, they provide no therapeutic agent that reduces pain and swelling and accelerates healing.



NSAIDS and narcotics Although these products do provide temporary relief, they are dangerous particularly for certain patients such as diabetics, arthritics, elderly, and the bed ridden and have significant adverse side effects.



Pain pumps These products are expensive, invasive, and pose a high risk for patients who are allergic to local anesthetics.



INTELLECTUAL PROPERTY

The Company has a number of trademarks and patents on innovative technology and has design and utilized patents pending.



Our trademarks and trade names are how we convey that the products we sell are “brand name” products. Our ownership of these trademarks and trade names is very important to our business as it allows us to compete based on the value and goodwill associated with these marks.

Issued Patents

Country


Apply. No.


Filing Date


Patent No.


Issue Date


Title


U.S.


10/384,101


03/06/203


7,551,957


06/23/2009


ELECTROMAGNETIC THERAPY DEVICE AND METHODS


U.S.


61/395,299


05/11/2010


-


-


BACK PAIN BELT


U.S.


29/375,754


09/27/2010


-


-


BACK PAIN DEVICE


U.S.


29/361,461


05/11/2010


USD638949S


05/31/2011


BACK PAIN BELT


U.S.


29/375,361


09/21/2012


USD643306S


08/16/2011


PRODUCT PACKAGE


Mexico


PA/a/2005/009446


03/03/2004


276793


06/22/2010


ELECTROMAGNETIC THERAPY DEVICE AND METHODS


China


201120086354.4


03/24/2011


The State of Intellectual Property granted this patent in August 2011.


08/08/2011


ELECTROMAGNETIC THERAPY DEVICE




Allowed Patents

Country


Appln. No.


Filing Date


Patent No.


Issue Date


Title


U.S.


10/384,101


03/06/203


7,551,957


06/23/2009


ELECTROMAGNETIC THERAPY DEVICE AND METHODS


Mexico


PA/a/2005/009446


03/03/2004


276793


06/22/2010


ELECTROMAGNETIC THERAPY DEVICE AND METHODS




Pending/Published Applications

Country


Appln. No.


Filing Date


Publn. No.


Publn. Date


Title


U.S.


10/442,448


05/21/2003


2004-0176805-A1


09/09/2004


ELECTROMAGNETIC THERAPY DEVICE AND METHODS


U.S.


12/627,829


11/30/2009


2010-0075211-A1


03/25/2010


BATTERY RETAINER


Australia


2004/220656


03/03/2004


ELECTROMAGNETIC THERAPY DEVICE AND METHODS


Canada


2,518,210


03/03/2004


ELECTROMAGNETIC THERAPY DEVICE AND METHODS


Korea


10-2005-7016620


03/03/2004


ELECTROMAGNETIC THERAPY DEVICE AND METHODS


U.S.


14563-0023P01


05/03/2011


PROVISIONAL PATENT RF INDUCED THERMAL TREATMENT OF TISSUE PAIN




Additionally, the Company continually innovates, has a monomaniac cost consciousness, and maintains a disruptive marketing pricing strategy to preclude introduction of competitive products.
CLINICAL RESEARCH STUDIES



Recently the Company completed four clinical trials. These studies investigated the use of our devices in relieving menstrual pain and musculoskeletal pain. Additionally, these studies directly compared our device to Tylenol® in treating delayed onset muscle soreness and directly compared our device to the competitive Torino medical device in treating post-operative pain after breast augmentation surgery.



The Company is conducting the following clinical studies:



Tufts University Dental School – 3rd Molar Extraction

Tufts University School of Dental Medicine, Department of Oral and Maxillofacial Surgery. This double blind, placebo controlled 100 patient study is evaluating post-operative pain and swelling. Ten million third molars are extracted annually in the U.S. The RecoveryRx product will address a significant unmet market need by offering a drug-free alternative to NSAIDs and opioids such as oxycodone and morphine, particularly for kidney compromised, arthritic and cardiovascular patients.



University of Toronto, Mt. Sinai Hospital - Caesarean Section

Principal investigator: Dr Jose Carvalho, Professor of Anesthesia and Obstetrics and Gynecology, University of Toronto, Director of Obstetric Anesthesia, Mount Sinai Hospital, This 200 patient double blind placebo controlled study. C-section, is a surgical procedure used to deliver a baby through an incision in the mother's abdomen and a second incision in the mother's uterus. Pain following Cesarean delivery remains the most common post-operative complaint, and the provision of effective and safe analgesia is very important. Pain can impede the mother’s ability to mobilize, and to care for and breastfeed her newborn baby, while prolonged immobility increases the risk of surgical complications.


Colorado Medical Center Denver - Venous Leg Ulcer Pain

Principal Investigator: Dr. Eric Jaakola, A 20-30 patient double blind placebo controlled study on venous leg ulcer pain.



Temple University School of Podiatry Philadelphia, Pa. Diabetic Neuropathy
Chief Investigator, Dr. Tracey Vlahovic, DPM, Evaluation of severe diabetic peripheral neuropathy pain.



University of British Columbia, Vancouver - Healing Plantar Fasciitis (heel pain)
Principal Investigator: Dr Jack Taunton, Professor, Division of Sports Medicine, Faculty of Medicine. A new clinical trial on plantar fasciitis utilizing BioElectronics’ ActiPatch device embedded into heel gel insoles allowing for a 24/7 therapy. This double blind, crossover study will assess the control of plantar fasciitis heel pain with long term follow up.



ORAL SURGERY PAIN MANAGEMENT: Neophytos Demetriades, D.D.S, Assistant Professor at Tufts University School of Dental Medicine is the Primary Investigator for this clinical trial. Dr. Demetriades is a member of the American Association of Oral and Maxillofacial Surgeons, and a fellow of the International Association of Oral and Maxillofacial Surgeons. Dr. Demetriades’ initial evaluation of the device generated promising results.


MANAGEMENT OF POSTOPERATIVE PAIN FOLLOWING CESAREAN SECTION: The Company is also conducting a study of Cesarean delivery, also known as a The clinical study will be led by Jose Carvalho, MD, PhD, FANZCA, FRCPC, Professor of Anesthesia and Obstetrics and Gynecology, University of Toronto, Director of Obstetric Anesthesia, Mount Sinai Hospital. The study is designed to assess pain at day 2 at rest and with movement. Pilot tests were very positive and a significant level of pain control was observed.

MANAGEMENT



Andrew J. Whelan, President & CEO

Mr. Whelan is a founder of the Company and has served as the President and Chairman of the Board of Directors since April 2000. He is a seasoned business executive with a strong financial, consulting and management background. From 1993 to April 2000, Mr. Whelan served as the President of P.A. Whelan & Company, Inc., a consulting firm owned by Mr. Whelan and his wife that specialized in the health care industry. Mr. Whelan was also a founder of Drug Counters, Inc., a chain of managed care retail pharmacies, where he served as President and Chief Executive Officer from 1992 until 1993. Drug Counters was sold to Diagnostek, Inc. in 1994. From 1984 until 1992, Mr. Whelan served as Chairman of the Board of Directors and President of Physicians’ Pharmaceutical Services, Inc., a public company of which he was a founder. Physicians Pharmaceutical Services was a charter member of the Maryland Chapter of “Inc’s Fastest Growing Companies in America.” Mr. Whelan received his B.S. in accounting from St. Peter’s College.



William Monn, Vice President of Production
Mr. Monn has over 30 years of experience in production management. As the Production Manager for Structural Systems Inc., he ensured timely shipments to customers, quality control and implemented safety and performance standards. As the Plant Manager for Hartz & Company, he led production improvements and initiatives that resulted in an outstanding quality reputation. He trained and supervised a staff of 347 and analyzed and improved departmental operations resulting in a 15% increase in productivity. Mr. Monn was the Production and Quality Assurance Manager of Burberry’s Wholesale LTD where he managed warehouse operations.


John Martinez, Senior Engineer

Mr. Martinez has served as Senior Engineer of the Company since April 2002. Mr. Martinez holds a Bachelors of Applied Science degree in Electronics Engineering Technology from ITT Technical Institute where he graduated with highest honors, and has worked exclusively in the electronics-engineering field for over ten years. His dedication and experience in multiple fields of engineering, including electronic, electromechanical, computer and communication systems, represent the foundation of his engineering talents. Mr. Martinez was the co-founder of MW Engineering, Inc., where he served as Senior Engineering Director from 1999 until April 2002. As Senior Engineering Director, Mr. Martinez was in charge of all of MW Engineering’s hardware, firmware and software development.



Dr. Ian Rawe, Ph.D., Director, Clinical Research
Dr Rawe obtained a Bachelor’s Degree in Biology, at the University of Hertfordshire and a Ph.D. in Biophysics at the Open University, Oxford, UK studying wound healing of the cornea. Dr. Rawe has extensive research experience spending 15 years conducting research on eye disease at Harvard Medical School. He brings expertise in designing and implementing research studies and publishing research articles. His role in the company will be to publish completed research studies, design and develop clinical trials utilizing the company’s technology. His experience in writing and obtaining grants from the NIH will allow the company to apply for small business innovation and research funding from the NIH SBIR/SBTT grant program.

BOARD OF DIRECTORS



Richard Staelin, Ph. D. – Chairman of the Board

Dr. Staelin joined the board in 2006. He is the Edward and Rose Donnell Chaired Professor of Business Admininstration at Duke’s Fuqua School of Business and the President of Informs Society for Marketing Scientists. He was the Associate Dean, The Fuqua School of Business, Duke University for 10 years, past Executive Director of Marketing Science Institute and has held numerous positions at the American Marketing Association (AMA) and The Institute of Management Science (TIMS). He was editor or an editorial board member of Marketing Science, Journal of Marketing Research, the Journal of Marketing, the Journal of Consumer Psychology and the Journal of Consumer Research. He has also consulted for the FDA and the FTC.



Andrew Whelan – Director

See above for detailed description.



Mary K. Whelan – Director

Ms. Whelan has served as a director of the Company since April 2002. Ms. Whelan also served as Vice President – Marketing from September 2002 until July 2003 and as Secretary from February 2002 until September 2004. Ms. Whelan currently is Founder and CEO, Revalent Media, Inc., a mobile marketing company. She was previously EVP at mPhase Technologies. She worked more than 20 years at AT&T Corp., Lucent Technologies, Inc. and Bell Labs. During that time Ms. Whelan successfully launched many high technology products. Ms. Whelan served as Vice President – eBusiness at Lucent Technologies. Prior to that, Ms. Whelan served as Lucent’s Vice President - Strategic Communications and Market Operations, in which capacity she was responsible for Lucent Technologies’ global marketing operations, including marketing communications and customer programs, and for the global sales support environment for the worldwide sales force. That environment included channel development, sales training, recognition and compensation. Ms. Whelan received extensive experience in all aspects of marketing and public relations at AT&T. She also had P&L responsibility for AT&T’s Directory business. Ms. Whelan is the sister of Andrew Whelan.

MEDICAL ADVISORY BOARD



Lawrence L. Michaelis, M.D., M.S. - Chairman of the BioElectronics Medical Advisory Board

Dr. Michaelis ia a physician, entrepreneur, business physician educator, and former Associate Dean Northwestern University Medical School. Author of over 130 peer-reviewed journal articles. NIH researcher, Chief Medical Officer, and Northwestern Hospital. Executive responsible for the Clinical Research Center of Northwestern University. President of a 400 + member multispecialty physician group. Chairman of the Board, VIRxSYS, a biotech company developing highly innovative genetic treatment and vaccines for HIV/AIDS and Cancer.



Kenneth McLeod, Ph.D. - Bioengineering Consultant

Dr. McLeod is Chairman and a Professor in the Bioengineering and Bioelectromagnetics Laboratory, State University of New York. Dr. McLeod is a pioneer researcher and author on the effect of energy on tissue, particularly at low power levels.



Laurie A. Casas, M.D. F.A.C.S.

Dr. Casas is an Associate Professor at Northwestern University Feinberg School of Medicine who has researched and reported 30 to 50% accelerated healing with the post operative use of ActiPatch Therapy.



William Van de Reis, M.D.

Dr. Van der Reis attended medical school at Cornell University Medical College. He completed both his internship and his residency at University of California, San Francisco. He performed a fellowship at The Orthopedic Specialty Hospital in Sports Medicine & Arthroscopy. Currently Dr. Van der Reis is a Team Physician for the U.S. Ski Team. Dr. Van der Reis is board certified from the American Academy of Orthopedic Surgeons and is a. His special interests include Sports Medicine, Arthroscopy, Shoulder and Knee Surgery.



Dr. Ian Rawe, Ph.D, Director, Clinical Research
Dr Rawe obtained a Bachelor’s Degree in Biology, at the University of Hertfordshire and a Ph.D in Biophysics at the Open University, Oxford, UK studying wound healing of the cornea. Dr. Rawe has extensive research experience spending 15 years conducting research on eye disease at Harvard Medical School. He brings expertise in designing and implementing research studies and publishing research articles. His role in the company will be to publish completed research studies, design and develop clinical trials utilizing the company’s technology. His experience in writing and obtaining grants from the NIH will allow the company to apply for small business innovation and research funding from the NIH SBIR/SBTT grant program.













My EANDE

More Information


Thursday, March 01, 2012 11:19:41 PM 799242